Non-Small Cell Lung Cancer

About
Mappings

OncoTree: Non-Small Cell Lung Cancer (oncotree:NSCLC)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
FDA (1) KRAS p.G12C Non-Small Cell Lung Cancer Adagrasib
FDA (1) HC (1) EGFR somatic variants Non-Small Cell Lung Cancer Afatinib
FDA (2) HC (1) v::ALK Non-Small Cell Lung Cancer Alectinib
FDA (1) HC (1) EGFR Exon 20 (Insertion) Non-Small Cell Lung Cancer Amivantamab, Carboplatin, Pemetrexed
FDA (1) HC (1) EGFR Exon 20 (Insertion) Non-Small Cell Lung Cancer Amivantamab
FDA (1) PD-L1 >= 1% Non-Small Cell Lung Cancer Atezolizumab
FDA (1) HC (1) PD-L1 >= 50% Non-Small Cell Lung Cancer Atezolizumab
FDA (1) PD-L1 >= 10% TIIC Non-Small Cell Lung Cancer Atezolizumab
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Carboplatin, Paclitaxel
FDA (1) EGFR somatic variants Non-Small Cell Lung Cancer Atezolizumab
FDA (1) v::ALK Non-Small Cell Lung Cancer Atezolizumab
FDA (2) BRAF p.V600E Non-Small Cell Lung Cancer Binimetinib, Encorafenib
FDA (1) HC (1) v::ALK Non-Small Cell Lung Cancer Brigatinib
FDA (1) HC (1) MET Exon 14 (Splice Site) Non-Small Cell Lung Cancer Capmatinib
FDA (1) HC (1) MET Exon 14 (Deletion) Non-Small Cell Lung Cancer Capmatinib
FDA (1) HC (1) Wild type ALK, Wild type EGFR, Wild type ROS1 Non-Small Cell Lung Cancer Carboplatin, Cemiplimab, Pemetrexed
FDA (1) PD-L1 >= 50%, Wild type ALK, Wild type EGFR, dMMR Non-Small Cell Lung Cancer Cemiplimab
FDA (1) HC (2) v::ALK Non-Small Cell Lung Cancer Ceritinib
FDA (1) HC (1) v::ALK Non-Small Cell Lung Cancer Crizotinib
FDA (1) HC (1) v::ROS1 Non-Small Cell Lung Cancer Crizotinib
FDA (2) HC (2) BRAF p.V600E Non-Small Cell Lung Cancer Dabrafenib, Trametinib
FDA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Dacomitinib
FDA (1) EGFR p.L858R Non-Small Cell Lung Cancer Dacomitinib
FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Pemetrexed, Tremelimumab
FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Pemetrexed, Tremelimumab
FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Gemcitabine, Tremelimumab
FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Gemcitabine, Tremelimumab
FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab
FDA (1) HC (1) v::ROS1 Non-Small Cell Lung Cancer Entrectinib
FDA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Erlotinib
FDA (1) EGFR p.L858R Non-Small Cell Lung Cancer Erlotinib
FDA (1) HC (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Gefitinib
FDA (1) HC (1) EGFR p.L858R Non-Small Cell Lung Cancer Gefitinib
FDA (1) HC (2) PD-L1 >= 1%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Ipilimumab, Nivolumab
FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Ipilimumab, Nivolumab, Pemetrexed
FDA (2) HC (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Ipilimumab, Nivolumab, Pemetrexed
FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
FDA (1) HC (2) v::ALK Non-Small Cell Lung Cancer Lorlatinib
FDA (1) EGFR Exon 20 (Insertion) Non-Small Cell Lung Cancer Mobocertinib
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Nivolumab, Paclitaxel
FDA (1) PD-L1 >= 1% Non-Small Cell Lung Cancer Ipilimumab, Nivolumab
FDA (3) HC (3) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Osimertinib
FDA (3) HC (3) EGFR p.L858R Non-Small Cell Lung Cancer Osimertinib
FDA (1) HC (1) EGFR p.L858R Non-Small Cell Lung Cancer Cisplatin, Osimertinib, Pemetrexed
FDA (1) HC (1) EGFR p.L858R Non-Small Cell Lung Cancer Carboplatin, Osimertinib, Pemetrexed
FDA (1) HC (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Carboplatin, Osimertinib, Pemetrexed
FDA (1) HC (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Cisplatin, Osimertinib, Pemetrexed
FDA (1) HC (1) EGFR p.T790M Non-Small Cell Lung Cancer Osimertinib
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Pembrolizumab, Pemetrexed
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Pembrolizumab, Pemetrexed
FDA (1) HC (1) PD-L1 >= 1%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Pembrolizumab
FDA (1) HC (1) PD-L1 >= 1% Non-Small Cell Lung Cancer Pembrolizumab
FDA (1) v::RET Non-Small Cell Lung Cancer Pralsetinib
FDA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Erlotinib, Ramucirumab
FDA (1) EGFR p.L858R Non-Small Cell Lung Cancer Erlotinib, Ramucirumab
FDA (1) HC (1) v::ROS1 Non-Small Cell Lung Cancer Repotrectinib
FDA (1) HC (1) v::RET Non-Small Cell Lung Cancer Selpercatinib
FDA (1) HC (1) KRAS p.G12C Non-Small Cell Lung Cancer Sotorasib
FDA (1) HC (1) MET Exon 14 (Splice Site) Non-Small Cell Lung Cancer Tepotinib
FDA (1) HC (1) MET Exon 14 (Deletion) Non-Small Cell Lung Cancer Tepotinib
FDA (1) ERBB2 oncogenic variants Non-Small Cell Lung Cancer Trastuzumab deruxtecan
FDA (2) HC (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Amivantamab, Lazertinib
FDA (2) HC (1) EGFR p.L858R Non-Small Cell Lung Cancer Amivantamab, Lazertinib
FDA (1) HC (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Amivantamab, Carboplatin, Pemetrexed
FDA (1) HC (1) EGFR p.L858R Non-Small Cell Lung Cancer Amivantamab, Carboplatin, Pemetrexed
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Paclitaxel
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Gemcitabine
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Pemetrexed
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Pemetrexed
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Nivolumab, Pemetrexed
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Gemcitabine, Nivolumab
FDA (1) v::NRG1 Non-Small Cell Lung Cancer Zenocutuzumab
FDA (1) v::ALK Non-Small Cell Lung Cancer Ensartinib
HC (1) EGFR oncogenic variants Non-Small Cell Lung Cancer Gefitinib
HC (1) EGFR oncogenic variants Non-Small Cell Lung Cancer Afatinib
HC (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Tremelimumab
HC (1) PD-L1 >= 50%, Wild type ALK, Wild type EGFR, Wild type ROS1 Non-Small Cell Lung Cancer Cemiplimab
HC (1) PD-L1 >= 50%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab
HC (1) PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab
FDA (1) v::ROS1 Non-Small Cell Lung Cancer Taletrectinib
FDA (1) EGFR somatic variants Non-Small Cell Lung Cancer Datopotamab deruxtecan
FDA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Datopotamab deruxtecan
FDA (1) EGFR p.L858R Non-Small Cell Lung Cancer Datopotamab deruxtecan
FDA (1) EGFR p.T790M Non-Small Cell Lung Cancer Datopotamab deruxtecan
FDA (1) HER2-negative, PR positive Non-Small Cell Lung Cancer Datopotamab deruxtecan
FDA (1) EGFR Exon 20 (Insertion) Non-Small Cell Lung Cancer Sunvozertinib